

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An immunostimulant composition comprising at least one agonist of the Toll-like 7 receptor or of the Toll-like 8 receptor, characterized in that it wherein the composition additionally comprises an agonist of the Toll-like 4 receptor.
2. (Currently Amended) The immunostimulant composition as claimed in the preceding claim, characterized in that wherein the agonist of the Toll-like 7 receptor or of the Toll-like 8 receptor is a compound different from the agonist of the Toll-like 4 receptor.
3. (Currently Amended) The immunostimulant composition as claimed in either of claims 1 and 2, characterized in that it claim 1, wherein the composition additionally comprises at least one vaccine antigen.
4. (Currently Amended) The immunostimulant composition as claimed in one of the preceding claims of claim 1, characterized in that wherein the agonist of the Toll-like 7 receptor is an imidazoquinolineamine derivative.
5. (Currently Amended) The immunostimulant composition as claimed in the preceding claim, characterized in that wherein the imidazoquinolineamine derivative is 4-amino-2-ethoxymethyl- α,α -dimethyl-1-H-imidazo[4,5c]quinoline-1-ethanol.
6. (Currently Amended) The immunostimulant composition as claimed in one of the preceding claims claim 1 or 5, characterized in that wherein the agonist of the Toll-like 4 receptor is ER804057.
7. – 8. (Canceled)